Further studies have found that in melanoma cells treated with BRAF inhibitor, the downregulation of transcription factor FOS related antigen-1 (FRA1) activates multiple signaling pathways, among which the PI3K/AKT/mTOR pathway plays a major role. This evidence concerns the gene BRAF and melanoma.